TFF Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — TFF Pharmaceuticals receives Nasdaq delisting notice; trading to suspend Dec 13

TFF Pharmaceuticals, Inc.

On Dec 4, 2024, Nasdaq notified TFFP of delisting based on Plan of Dissolution, public interest concerns, and listing compliance issues.
Trading of TFFP common stock will be suspended at the opening of business on December 13, 2024.
Nasdaq will file Form 25-NSE with the SEC to remove the securities from listing and registration.
Company states it does not intend to appeal the delisting determination.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

TFF Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b)).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101, 5110(b)

Exact text from the filing

December 4, 2024, TFF Pharmaceuticals, Inc. (“Company”) received a determination letter (the “Delisting Notification”) from the Nasdaq Stock Market (“Nasdaq”) stating that the Nasdaq staff determined, in accordance with Nasdaq Listing Rules 5101 and 5110(b) and Nasdaq Listing Rule IM 5101-1, that the Company’s common stock will be delisted from The Nasdaq Stock Market. The Delisting Notification states that the Nasdaq staff’s determination was based on (i) the Company’s previously announced Plan of Dissolution and associated public interest concerns raised by it; (ii) concerns regarding the re

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-24-107409

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.